1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Seiler R, Thalmann GN, Fleischmann A,
Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E,
Bohle A, Palou RJ, et al: MMP-2 and MMP-9 in lymph-node-positive
bladder cancer. J Clin Pathol. 64:1078–1082. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Herbst RS, Eckhardt SG, Kurzrock R,
Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA,
Tohnya TM, Lum BL, et al: Phase I dose-escalation study of
recombinant human Apo2L/TRAIL, a dual proapoptotic receptor
agonist, in patients with advanced cancer. J Clin Oncol.
28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Galligan L, Longley DB, McEwan M, Wilson
TR, McLaughlin K and Johnston PG: Chemotherapy and TRAIL-mediated
colon cancer cell death: the roles of p53, TRAIL receptors, and
c-FLIP. Mol Cancer Ther. 4:2026–2036. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yin S, Rishi AK and Reddy KB:
Anti-estrogen-resistant breast cancer cells are sensitive to
cisplatin plus TRAIL treatment. Oncol Rep. 33:1475–1480.
2015.PubMed/NCBI
|
7
|
Wang D and Shi L: High-level expression,
purification, and in vitro refolding of soluble tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL). Appl Biochem
Biotechnol. 157:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ismail B, Ghezali L, Gueye R, Limami Y,
Pouget C, Leger DY, Martin F, Beneytout JL, Duroux JL, Diab-Assaf
M, et al: Novel methylsulfonyl chalcones as potential
antiproliferative drugs for human prostate cancer: Involvement of
the intrinsic pathway of apoptosis. Int J Oncol. 43:1160–1168.
2013.PubMed/NCBI
|
9
|
Kauntz H, Bousserouel S, Gossé F and Raul
F: The flavonolignan silibinin potentiates TRAIL-induced apoptosis
in human colon adenocarcinoma and in derived TRAIL-resistant
metastatic cells. Apoptosis. 17:797–809. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Shin EA, Sohn EJ, Won G, Choi JU, Jeong M,
Kim B, Kim MJ and Kim SH: Upregulation of microRNA135a-3p and death
receptor 5 plays a critical role in Tanshinone I sensitized
prostate cancer cells to TRAIL induced apoptosis. Oncotarget.
5:5624–5636. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ismail B, Fagnere C, Limami Y, Ghezali L,
Pouget C, Fidanzi C, Ouk C, Gueye R, Beneytout JL, Duroux JL, et
al: 2′-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced
apoptosis in prostate cancer cells. Anticancer Drugs. 26:74–84.
2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang T, Qu S, Shi Q, He D and Jin X:
Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis
in human bladder cancer cells through mTOR/S6K1-mediated
downregulation of Mcl-1. Int J Mol Sci. 15:3154–3171. 2014.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang T, Wang X, He D, Jin X and Guo P:
Metformin sensitizes human bladder cancer cells to TRAIL-induced
apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Anticancer Drugs. 25:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
|